Pharmaceuticals APAC

APAC Cancer Immunotherapy Market Analysis, 2024–2034

APAC Cancer Immunotherapy Market Industry Trends and Forecast to 2034: Segmented by (Type, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

APAC · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $23.58 Bn Estimated value
Estimate 2025 $26.39 Bn 19.5% of the global market
Projected 2034 $72.60 Bn 175.1% Adds $46.21 Bn over 9 forecast years
CAGR 2025–2034 11.9% Faster than 64% of 180 Pharmaceuticals markets here
Key players 5
  • APAC is 19.47% of the global market.
  • Among regions, the largest is North America at $66.95 Bn.
  • Fastest growing: Africa at 12.6% a year.
  • APAC ranks 2nd of 6 by size among regions.

Market size projection

APAC

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$46.21 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Cancer Immunotherapy Market market size by year, APAC
YearMarket sizeChange that yearSince 2025
2024 (estimate) $23.58 Bn — —
2025 (base) $26.39 Bn +$2.81 Bn —
2026 (forecast) $29.53 Bn +$3.14 Bn +11.9%
2027 (forecast) $33.05 Bn +$3.51 Bn +25.2%
2028 (forecast) $36.98 Bn +$3.93 Bn +40.1%
2029 (forecast) $41.38 Bn +$4.40 Bn +56.8%
2030 (forecast) $46.30 Bn +$4.92 Bn +75.4%
2031 (forecast) $51.81 Bn +$5.51 Bn +96.3%
2032 (forecast) $57.98 Bn +$6.17 Bn +119.7%
2033 (forecast) $64.88 Bn +$6.90 Bn +145.8%
2034 (forecast) $72.60 Bn +$7.72 Bn +175.1%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $135.53 Bn
  2. North America $66.95 Bn
  3. US $52.97 Bn
  4. Europe $25.90 Bn
  5. APAC (this report) $26.39 Bn
  6. Canada $10.94 Bn
  7. China $11.03 Bn
  8. Japan $8.86 Bn
  9. Latin America $5.57 Bn
  10. Middle East $4.86 Bn
  11. Germany $4.14 Bn
  12. France $3.64 Bn
  13. UK $3.09 Bn
  14. Brazil $3.17 Bn
  15. India $2.95 Bn
  16. Spain $2.75 Bn
  17. Italy $2.77 Bn
  18. Ecuador $2.72 Bn
  19. Saudi Arabia $2.26 Bn
  20. Africa $2.23 Bn
  21. Mexico $2.04 Bn
  22. Australia $1.92 Bn
  23. Russia $1.57 Bn
  24. New Zealand $1.34 Bn
  25. South Africa $978.9 Mn
  26. UAE $601.7 Mn
  27. Egypt $410.4 Mn
  28. Philippines $315.1 Mn
  29. Malaysia $234.9 Mn
  30. Hong Kong $202.1 Mn
  31. Singapore $178.8 Mn
  32. Thailand $176.3 Mn
  33. Kenya $96.0 Mn

The APAC Cancer Immunotherapy Market Analysis Executive Summary

Cancer immunotherapy helps the immune system fight cancer, using checkpoint inhibitors, cell therapies, vaccines and other immune drugs.

Key segments of the cancer Immunotherapy market include type (Checkpoint Inhibitors, Cell Therapies and Cancer Vaccines) and indication (Lung Cancer, Melanoma and Blood Cancers).

APAC Cancer Immunotherapy Market Dynamics

Market Growth Drivers

Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the cancer Immunotherapy market. Faster approvals and new combinations are improving survival.

Opportunity

Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the cancer Immunotherapy market.

Market Restraints

High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the cancer Immunotherapy market, especially in low- and middle-income countries.

Competitive Landscape for Cancer Immunotherapy Market in APAC

The cancer Immunotherapy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Cancer Immunotherapy Market in APAC

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for cancer Immunotherapy. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in APAC.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Cancer Immunotherapy right now, from free public sources.

Clinical trials

884 active trials in China, India, Japan, Australia, Hong Kong, Philippines, Singapore, Thailand, Malaysia, New Zealand, Bangladesh, Afghanistan, Indonesia, Myanmar, Nepal and Pakistan

Recruiting, about to start, or running now. Counted across the 16 countries we report on in APAC.

Top trial sponsors (worldwide)

  1. Beijing Biotech 19 active trials on ClinicalTrials.gov (opens in a new tab)
  2. BioNTech 15 active trials on ClinicalTrials.gov (opens in a new tab)
  3. AstraZeneca 14 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Inmunotek S.L. 8 active trials on ClinicalTrials.gov (opens in a new tab)
  5. ImmunityBio, Inc. 7 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Latest research 16,264 papers since 2021 (worldwide)

  1. Ligand/receptor-based chimeric antigen receptors: a promising alternative to conventional scFv designs in cancer immunotherapy. Transplantation and cellular therapy, 2026
  2. Microneedle-based delivery strategies for cancer immunotherapy. International journal of pharmaceutics, 2026
  3. Acute Neurotoxicity Syndromes from Immunotherapy: Emergency and ICU Management. Seminars in neurology, 2026
  4. Spatiotemporal dynamics of adoptively transferred stem-like CD8(+) T cells in the tumor microenvironment following vaccination. Cell reports. Medicine, 2026
  5. Differentiation of stem-like CD4(+) T cells modulates early effector responses in colorectal cancer. Science (New York, N.Y.), 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Cancer Immunotherapy in context

Questions, answered with public data

How many clinical trials on Cancer Immunotherapy are running in APAC?
884 studies are recruiting, active or about to start in APAC, counted across the 16 countries we report on there.[1]
How much research is published on Cancer Immunotherapy?
PubMed lists 16,264 papers added since January 2021 that match this market, worldwide.[2]

[1] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in APAC. Retrieved 12 Nov 2026.

[2] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.

Free data on this topic

Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Cancer Immunotherapy in APAC? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard

From our blog

Brain Cancer Diagnosis: Imaging and New BiomarkersAbout 321,000 people were diagnosed with brain and nervous system tumours in 2022, and about 248,000 died… Bioinformatics: Making Sense of Health DataSequencing a human genome fell from about $50 million in 2003 to under $1,500 by late 2015. Bioinformatics… Dermatology Diagnostics: AI and Skin HealthSkin cancers caused over 1.5 million new cases in 2022. Imaging and AI tools are changing how skin conditions…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in APAC

See all
Same topic, other categories

Related on oncology

See the topic